DSpace Repository

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis

Show simple item record

dc.contributor.author Peloquin, Charles A.
dc.contributor.author Phillips, Patrick P. J.
dc.contributor.author Mitnick, Carole D.
dc.contributor.author Eisenach, Kathleen
dc.contributor.author Patientia, Ramonde F.
dc.contributor.author Lecca, Leonid
dc.contributor.author Gotuzzo, Eduardo
dc.contributor.author Gandhi, Neel R.
dc.contributor.author Butler, Donna
dc.contributor.author Diacon, Andreas H.
dc.contributor.author Martel, Bruno
dc.contributor.author Santillan, Juan
dc.contributor.author Hunt, Kathleen Robergeau
dc.contributor.author Vargas, Dante
dc.contributor.author von Groote-Bidlingmaier, Florian
dc.contributor.author Seas, Carlos
dc.contributor.author Dianis, Nancy
dc.contributor.author Moreno-Martinez, Antonio
dc.contributor.author Kaur, Pawandeep
dc.contributor.author Horsburgh, C. Robert
dc.date.accessioned 2018-11-30T17:17:13Z
dc.date.available 2018-11-30T17:17:13Z
dc.date.issued 2018
dc.identifier.uri https://hdl.handle.net/20.500.12866/4096
dc.description.abstract Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. en_US
dc.language.iso eng
dc.publisher American Society for Microbiology
dc.relation.ispartof urn:issn:1098-6596
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject tuberculosis en_US
dc.subject antitubercular agents en_US
dc.subject levofloxacin en_US
dc.subject pharmacokinetics en_US
dc.title Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1128/aac.00770-18
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.05


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics